Plain-English translation of NCT07386730 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are studying how psilocybin — a naturally occurring compound found in certain mushrooms — affects brain activity and inflammation in older adults who experience low well-being or loss of joy. This is an early-stage study designed to understand whether the medication is safe and how it might work in the brain. Participants will receive a single dose and be monitored closely with brain scans and blood tests over three months.
Many older adults experience persistent low mood and loss of interest in things they once enjoyed, but current treatments don't work well for everyone. Researchers want to explore whether this medication might help improve mood and brain health by reducing inflammation and changing how the brain processes information.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will visit the research center 3–4 times in person and have 3–4 remote visits over about three months. Most visits last 1–3 hours, but the main dosing visit (where you take the medication) will last 8–12 hours so researchers can monitor your brain activity, heart rate, and well-being throughout the day. You'll have brain scans (MRI), blood tests, and wear a device that tracks your heart rate and activity. Researchers will randomly assign you to receive one of four different doses of the medication or a comparison drug to help them understand which dose works best and is safest.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
United States